Waltham, Massachusetts & Boulder, Colorado, January 26, 2026 — Cogent Biosciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for bezuclastinib in combination with sunitinib for the treatment of patients with Gastrointestinal Stromal Tumors (GIST) who have previously received imatinib. The designation recognizes the therapy’s potential to provide a substantial improvement over currently available treatments for this serious and life-threatening cancer. Cogent confirmed that it plans to submit a New Drug Application (NDA) under the FDA’s Real-Time Oncology Review (RTOR) pathway, with full NDA submission expected by April 2026.
Science Significance
Bezuclastinib is a selective tyrosine kinase inhibitor designed to potently inhibit KIT mutations, including KIT D816V and KIT exon 17 mutations, which play a key role in driving GIST tumor growth. The PEAK trial results showed that patients receiving the combination therapy achieved a median progression-free survival (mPFS) of 16.5 months, compared to 9.2 months for those receiving sunitinib monotherapy. This improvement represents a clinically meaningful and statistically significant benefit, reinforcing the drug’s scientific promise in targeting oncogenic signaling pathways central to tumor proliferation and resistance mechanisms. Importantly, the safety profile remained consistent with known sunitinib risks, and no new safety concerns were observed.
Regulatory Significance
The Breakthrough Therapy Designation is intended to expedite development and review of drugs for serious conditions when early clinical evidence indicates substantial improvement over existing therapies. Cogent’s program has also been accepted into the FDA’s Real-Time Oncology Review (RTOR) program, allowing components of the NDA to be reviewed before the full application is submitted. This regulatory pathway aims to accelerate access to effective cancer therapies by reducing review timelines while maintaining rigorous safety and efficacy standards. Cogent plans to present full PEAK trial results at a major medical meeting in the first half of 2026 and expects to begin a Phase 2 trial in mid-2026 evaluating the combination therapy in first-line GIST patients with exon 9 mutations.
Advertisement
Business Significance
For Cogent Biosciences, the FDA designation represents a major strategic milestone that strengthens the company’s oncology pipeline and enhances its commercial potential in precision cancer therapy. GIST represents a niche but high-value oncology market with limited treatment options after imatinib resistance develops. The Breakthrough Therapy Designation may improve Cogent’s attractiveness to investors, pharmaceutical partners, and licensing opportunities, supporting long-term business growth. The accelerated regulatory pathway also positions Cogent to potentially bring a first-in-class therapy to market faster, strengthening its competitive standing in targeted oncology.
Patients’ Significance
For patients with imatinib-resistant GIST, treatment options have remained limited for over twenty years. The bezuclastinib-sunitinib combination offers renewed hope by delivering a therapy that meaningfully extends progression-free survival and potentially improves overall quality of life. Patients facing advanced disease often experience poor prognosis and limited alternatives, making this advancement particularly impactful. If approved, the therapy could become a new standard of care, offering patients a longer window of disease control and improved clinical outcomes.
Policy Significance
The FDA’s Breakthrough Therapy Designation reflects broader public-health and oncology policy goals aimed at accelerating access to life-saving cancer treatments. Supporting innovative targeted therapies aligns with global efforts to advance precision oncology and improve survival outcomes in genetically defined cancers. Cogent’s participation in RTOR further supports regulatory modernization by promoting faster yet scientifically rigorous drug review processes, contributing to policy frameworks that prioritize patient access to transformative cancer treatments.
Cogent Biosciences’ announcement on January 26, 2026 marks a pivotal step in the advancement of bezuclastinib for Gastrointestinal Stromal Tumors, signaling meaningful progress for patients with treatment-resistant disease. With Breakthrough Therapy Designation granted, NDA submission planned for April 2026, and additional clinical trials on the horizon, the company is positioned to potentially deliver the first major new GIST treatment in over twenty years. As development continues, bezuclastinib stands as a promising example of precision oncology innovation addressing a long-standing unmet medical need.
Source: Cogent Biosciences, Inc. press release
